Trospium chloride (cas 10405-02-4) for overactive bladder may induce central nervous system adverse events
-
Add time:08/01/2019 Source:sciencedirect.com
BackgroundAnticholinergic drugs constitute the first-line pharmacologic treatment for overactive bladder (OAB). Of the various anticholinergic agents available, Trospium chloride (cas 10405-02-4) appears to have potentially favorable chemical and pharmacologic properties leading to reduce the incidence of central nervous system (CNS) adverse reactions, since their ability to cross the blood-brain barrier is reduced (relative to other drugs in this therapeutic class).
We also recommend Trading Suppliers and Manufacturers of Trospium chloride (cas 10405-02-4). Pls Click Website Link as below: cas 10405-02-4 suppliers
Prev:Increasing dissolution of Trospium chloride (cas 10405-02-4) by co-crystallization with urea
Next:Extended-Release Trospium chloride (cas 10405-02-4) Improves Quality of Life in Overactive Bladder) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effects of Tolterodine and Trospium chloride (cas 10405-02-4) on Renal Damage Induced by Partial Upper Urinary Tract Obstruction08/08/2019
- Effects of Combined Use of Trospium chloride (cas 10405-02-4) and Melatonin on In Vitro Contractility of Rat Urinary Bladder08/07/2019
- Lipid-based intravesical drug delivery systems with controlled release of Trospium chloride (cas 10405-02-4) for the urinary bladder08/06/2019
- Role of Trospium chloride (cas 10405-02-4) in Brachytherapy-Related Detrusor Overactivity08/05/2019
- Factors of adherence to treatment with trospium in employees08/04/2019
- Once Daily Trospium chloride (cas 10405-02-4) is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial08/03/2019
- Extended-Release Trospium chloride (cas 10405-02-4) Improves Quality of Life in Overactive Bladder08/02/2019
- Increasing dissolution of Trospium chloride (cas 10405-02-4) by co-crystallization with urea07/31/2019
- Trospium chloride (cas 10405-02-4) is absorbed from two intestinal “absorption windows” with different permeability in healthy subjects07/30/2019